Obstet Gynecol Sci.  2022 May;65(3):266-272. 10.5468/ogs.21261.

Effect of autologous platelet-rich plasma for treatment of recurrent pregnancy loss: a randomized controlled trial

• Nazari L
• Salehpour S
• Hosseini S
• Hashemi T
• Borumandnia N
• Azizi E

• KMID: 2529829
• DOI: http://doi.org/10.5468/ogs.21261

Abstract

Objective
Recurrent pregnancy loss (RPL) is a fertility problem for which no exact mechanism of abortion or efficient treatment has been described. This study was conducted between 2018 and 2019 to investigate the effectiveness of autologous platelet-rich plasma (PRP) in improving the live birth rate of women with RPL who required in vitro fertilization (IVF).
Methods
A total of 63 patients with at least two previous pregnancy losses and no specific cause detected for the RPL were included and randomly assigned into two groups (PRP and control). Intrauterine infusion of 0.5 mL of autologous PRP was performed 48 hours before embryo transfer in the PRP group. Women in the control group received standard treatment.
Results
Forty patients completed the study. The baseline and cycle characteristics of the participants did not differ significantly between the PRP and control groups. The clinical pregnancy rate was higher in the PRP group (35% vs. 20%, P=0.288). The live birth rate was 15% in the PRP group, but no live births were recorded in the control group (P=0.231).
Conclusion
This is the first study to show that intrauterine infusion of PRP in patients with RPL who undergo IVF may increase the chance of live birth.

Keyword

Platelet-rich plasma; Live-birth; Recurrent pregnancy loss; fertilization

Figure

• 

  Fig. 1 The consolidated standards of reporting trials flowchart. PRP, platelet-rich plasma.

Reference

References

1. Egerup P, Kolte AM, Larsen EC, Krog M, Nielsen HS, Christiansen OB. Recurrent pregnancy loss: what is the impact of consecutive versus non-consecutive losses? Hum Reprod. 2016; 31:2428–34.

2. The ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss. 1st ed. Oxford: Oxford University Press;2018.

3. Ticconi C, Pietropolli A, Di Simone N, Piccione E, Fazleabas A. Endometrial immune dysfunction in recurrent pregnancy loss. Int J Mol Sci. 2019; 20:5332.

4. Di Nicuolo F, D’Ippolito S, Castellani R, Rossi ED, Masciullo V, Specchia M, et al. Effect of alpha-lipoic acid and myoinositol on endometrial inflammasome from recurrent pregnancy loss women. Am J Reprod Immunol. 2019; 82:e13153.

5. Baradwan S, Abdulghani SH, Abuzaid M, Khadawardi K, Alshahrani MS, Al-Matary A, et al. 17-alpha hydroxy-progesterone caproate for the prevention of recurrent preterm birth among singleton pregnant women with a prior history of preterm birth: a systematic review and meta-analysis of six randomized controlled trials. Obstet Gynecol Sci. 2021; 64:484–95.

6. Bagheri A, Chianeh YR, Rao P. Role of angiogenic factors in recurrent pregnancy loss. Int J Reprod Contracept Obstet Gynecol. 2013; 2:497–503.

7. Dhaenens L, Lierman S, De Clerck L, Govaert E, Deforce D, Tilleman K, et al. Endometrial stromal cell proteome mapping in repeated implantation failure and recurrent pregnancy loss cases and fertile women. Reprod Biomed Online. 2019; 38:442–54.

8. Tan SY, Hang F, Purvarshi G, Li MQ, Meng DH, Huang LL. Decreased endometrial vascularity and receptivity in unexplained recurrent miscarriage patients during midluteal and early pregnancy phases. Taiwan J Obstet Gynecol. 2015; 54:522–6.

9. Daher S, de Arruda Geraldes Denardi K, Blotta MH, Mamoni RL, Reck AP, Camano L, et al. Cytokines in recurrent pregnancy loss. J Reprod Immunol. 2004; 62:151–7.

10. Lea RG, Underwood J, Flanders KC, Hirte H, Banwatt D, Finotto S, et al. A subset of patients with recurrent spontaneous abortion is deficient in transforming growth factor beta-2-producing “suppressor cells” in uterine tissue near the placental attachment site. Am J Reprod Immunol. 1995; 34:52–64.

11. An HJ, Kim JH, Ahn EH, Kim YR, Kim JO, Park HS, et al. 3′-UTR polymorphisms in the vascular endothelial growth factor gene (VEGF) contribute to susceptibility to recurrent pregnancy loss (RPL). Int J Mol Sci. 2019; 20:3319.

12. Sun Y, Chen M, Mao B, Cheng X, Zhang X, Xu C. Association between vascular endothelial growth factor polymorphism and recurrent pregnancy loss: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2017; 211:169–76.

13. Gobbi G, Vitale M. Platelet rich plasma for biological therapy: applications and limits. Maffulli N, editor. Platelet rich plasma in musculoskeletal practice. London: Springer;2016. p. 175–98.

14. Mejia HA, Bradley JP. The effects of platelet-rich plasma on muscle: basic science and clinical application. Oper Tech Sports Med. 2011; 19:149–53.

15. Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet rich plasma. Maffulli N, editor. Platelet rich plasma in musculoskeletal practice. London: Springer;2016. p. 1–29.

16. Nazari L, Salehpour S, Hosseini MS, Hashemi Moghanjoughi P. The effects of autologous platelet-rich plasma in repeated implantation failure: a randomized controlled trial. Hum Fertil (Camb). 2019; 23:209–13.

17. Kuroda K. Impaired endometrial function and unexplained recurrent pregnancy loss. Hyperten Res Pregnancy. 2019; 7:16–21.

18. Sipahi M. Effects of autologous platelet-rich plasma on endometrium thickness and pregnancy rates during intrauterine insemination. Middle Black Sea J Health Sci. 2019; 5:63–6.

19. Nazari L, Salehpour S, Hoseini S, Zadehmodarres S, Ajori L. Effects of autologous platelet-rich plasma on implantation and pregnancy in repeated implantation failure: a pilot study. Int J Reprod Biomed. 2016; 14:625–8.

20. Coksuer H, Akdemir Y, Ulas Barut M. Improved in vitro fertilization success and pregnancy outcome with autologous platelet-rich plasma treatment in unexplained infertility patients that had repeated implantation failure history. Gynecol Endocrinol. 2019; 35:815–8.

21. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010; 93:1234–43.

22. Nazari L, Salehpour S, Hoseini S, Zadehmodarres S, Azargashb E. Effects of autologous platelet-rich plasma on endometrial expansion in patients undergoing frozen-thawed embryo transfer: a double-blind RCT. Int J Reprod Biomed. 2019; 17:443–8.

23. Kim H, Shin JE, Koo HS, Kwon H, Choi DH, Kim JH. Effect of autologous platelet-rich plasma treatment on refractory thin endometrium during the frozen embryo transfer cycle: a pilot study. Front Endocrinol (Lausanne). 2019; 10:61.

24. El Hamedi MA, Salem HA. Platelet rich plasma in repeated implantation failure in women with thin endometrium thickness. Egypt J Hosp Med. 2019; 77:5873–5.

25. Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. Treatment of thin endometrium with autologous platelet-rich plasma: a pilot study. JBRA Assist Reprod. 2017; 21:54–6.

26. Molina A, Sánchez J, Sánchez W, Vielma V. Platelet-rich plasma as an adjuvant in the endometrial preparation of patients with refractory endometrium. JBRA Assist Reprod. 2018; 22:42–8.

27. Torky AMMAE, Amer MIM, Ahmed MES, Kamal RM. The value of using platelet rich plasma after hysteroscopic analysis of severe intrauterine adhesions (a randomized controlled trial). Egypt J Hosp Med. 2018; 71:2869–74.

28. Lash GE, Innes BA, Drury JA, Robson SC, Quenby S, Bulmer JN. Localization of angiogenic growth factors and their receptors in the human endometrium throughout the menstrual cycle and in recurrent miscarriage. Hum Reprod. 2012; 27:183–95.

29. Ferrara N, Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS. 1997; 79:209–32.